AzTrials
AzTrials

Malignant Biliary ObstructionNCT03215108

Comparison Between Novel Flower-type Covered Stent and Conventional Covered Stent

A study testing Endoscopic Retrograde CholangioPancreatography(ERCP) in people with Malignant Biliary Obstruction, run by Samsung Medical Center at 1 site in South Korea.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of this animal study is determining the technical feasibility of the novel flower-type covered self-expandable metal stent (F-CSEMS) and investigating whether the novel flower-type covered self-expandable metal stent (F-CSEMS) could prevent cholecystitis and pancreatitis, comparing with conventional covered… Read more about this study

Who is it for?
Ages 19 to 85 years
Conditions the study is for
Malignant Biliary Obstruction
What is being tested?
Endoscopic Retrograde CholangioPancreatography(ERCP)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
256 participants
Where
1 siteSouth Korea
Study dates
12 Jul 2017to 31 Dec 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults from 19 to 85 years of age who have voluntarily agreed to the clinical trial and signed a written agreement
  • Patients with malignant extrahepatic bile duct obstruction without surgery

Who cannot join

  • Patients who had already undergone surgical biliary drainage
  • Patients who previously underwent percutaneous spinal cholecystectomy (PTGBD)
  • Patients who underwent conventional metal-on-metal self-expandable metal stents (C-CSEMS)
  • Patients who underwent biliary plastic stent implantation for more than 15 days
  • Patients with malignant stricture of the intrahepatic bile duct and patients with stenosis within 2 cm of the liver
  • Patients whose expected life expectancy is less than 3 months
  • Pregnant patient
  • Patients who can not undergo endoscopic procedures based on the judgment of the researcher

Trial locations and contacts

1 site in 1 country.

South Korea1 site, 1 recruiting
  • SamsungMC

    Seoul, KS013

    Jae Keun Park, MD, +82-3410-3409, jaekeunjaekeun.park@samsung.com

    Recruiting

Other trials in South Korea

About this study

Official title: Comparison Between Novel Flower-type Covered Stent and Conventional Covered Stent in Malignant Extrahepatic Biliary Obstruction: Prospective Randomized Multicenter Study

The aim of this animal study is determining the technical feasibility of the novel flower-type covered self-expandable metal stent (F-CSEMS) and investigating whether the novel flower-type covered self-expandable metal stent (F-CSEMS) could prevent cholecystitis and pancreatitis, comparing with conventional covered self-expandable metal stent (C-CSEMS).

Read the detailed description

Covered self-expandable metal stent (C-CSEMS) has the risk of obstruction of the cystic duct, and the main and branch pancreatic ducts due to strong radial force and covering material, which results in cholecystitis and pancreatitis.

A flower-type covered self-expandable metal stent (F-CSEMS) having a five-petal-shaped design with side grooves was constructed to prevent the obstruction of the cystic duct orifice.

This study investigated the value of the F-CSEMS in protection for cholecystitis and pancreatitis.

The investigators will enroll patients with distal MBO (Malignant Biliary Obstruction) who received placement at the Samsung Medical Center. Transpapillary flower-type covered self-expandable metal stent (F-CSEMS) placements will be included in this study.

The diagnosis of MBO will be based on imaging and/or pathological findings. Malignancy was proved by histopathological confirmation obtained by endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA), bile duct biopsy (cytology), pancreatic duct cytology, or liver biopsy.

The investigators will evaluate the frequency of pancreatitis and cholecystitis.

Furthermore, the investigators will evaluate various parameters to clarify the predictive factors of pancreatitis and cholecystitis. The following 10 variables will be evaluated in pancreatitis by univariate analysis: [1] sex, [2] age, [3] primary disease, [4] Covered type (partially or fully), [5] SEMS with high AF, [6] F-CSEMS with high RF, [7] EST before F-CSEMS, [8] previous biliary stent, [9] contrast injection into the pancreatic duct (pancreatogram), and [10] the position of the distal stent edge.

The following 11 variables will be evaluated in cholecystitis by univariate analysis: [1] sex, [2] age, [3] regions of stricture, [4] F-CSEMS with high AF AF (axial force), [5] F-CSEMS with high RF, [6] previous biliary stent, [7] gallbladder stone, [8] contrast injection into the gallbladder (GB injection), [9] involvement to the orifice of the cystic duct (OCD), [10] position of distal stent edge, and [11] cystic duct occlusion by F-CSEMS.

--------------------------------------------------------------------------------------------------------

software: nQuery + nTerim (version 4.0)

  • One-sided Chi-square test for proportion comparison

H0: p1=p2 vs H1: p1>p2 (The incidence of complications in the flower-type covered stent is smaller than in the conventional stent.)

p1 = incident rate of complication in full covered stent group p2 = incident rate of complication in flower-type covered stent group

  • Set p1(incident rate of complication in full covered stent group) = 15% = 0.15
  • expected % decrement in incidence rate = 40%, 50%, 60%, 70% --> p2 = 0.09, 0.075, 0.06, 0.045
  • Significance level (alpha) = 0.05
  • Maximum number of patients who can be enrolled = 10 per month at SMC = 120 per year
  • Expected enroll period = 1 year = 12 months
  1. Sample size calculation with targeted power of 80% Expected % decrement in incidence rate 70% p2 4.5% Required n per group 116 Required total sample size 232 Required enroll period (year) 1.9
  2. Power calculation with a total sample size of 232 (116 per group) Expected % decrement in incidence rate 40% 50% 60% 70% p2 9.0% 7.5% 6.0% 4.5% Expected power (%) 32 48 64 80
  3. Minimum % decrement to be detected with power of 80% Planned enroll period (year) 1 1.5 2 2.5 3 Enroll-able n per group 60 90 120 150 180 Enroll-able total sample size 120 180 240 300 360 Minimum % decrement to be detected 93.33% 78.70% 68.70% 62.70% 58.00% Expected p2 1.0% 3.2% 4.7% 5.6% 6.3%
Being tested
Endoscopic Retrograde CholangioPancreatography(ERCP)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Endoscopic Retrograde CholangioPancreatography(ERCP)Device

    This study is prospective randomized multicenter study by using Endoscopic Retrograde CholangioPancreatography(ERCP). Comparison between Novel flower-type covered stent and Conventional covered stent in malignant extrahepatic biliary obstruction will be conducted after stent insertion by using Endoscopic Retrograde CholangioPancreatography(ERCP).

Study groups in NCT03215108
Study groupRoleWhat they receive
Flower-CSEMSExperimentalEGIS Flower Biliary Full Covered Stent(Flower-CSEMS), Bile Duct Stent, (S \& G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP).
Receives: Device: Endoscopic Retrograde CholangioPancreatography(ERCP)
Conventional-CSEMSExperimentalConventional-CSEMS (S \& G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP).
Receives: Device: Endoscopic Retrograde CholangioPancreatography(ERCP)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pancreatitis, Cholecystitis - Occurrence rate : %

    The incidence of pancreatitis is calculated using percentiles.

    Measured: 3 months after procedure

  2. Pancreatitis, Cholecystitis - Severity

    The extent of each side effect is described in the Adverse Reactions Report according to the National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) Rating System version 4.0.

    Measured: 3 months after procedure

Secondary outcomes (2)
  1. Stent-related adverse events

    Post -ERCP pancreatitis, Severity of pancreatitis, Bleeding, Microperforation

    Measured: 6 months after procedure

  2. Stent patency

    We followed up the stent patency until the time of patient death or stent occlusion.

    Measured: 6 months after procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jul 2017
  2. Study start12 Jul 2017 (estimated)
  3. Primary completion1 Jun 2019 (estimated)
  4. Study completion31 Dec 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Flower-CSEMS vs. Conventional-CSEMS
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
256 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03215108
Sponsor's protocol ID
2017-03-098-001
Status last verified
May 2017
First submitted
26 May 2017
Last updated
12 Jul 2017
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Endoscopic Retrograde CholangioPancreatography(ERCP) in people with Malignant Biliary Obstruction, run by Samsung Medical Center at 1 site in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 12 Jul 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Jong Kyun Lee, MD PhD (+82-2-3410-3409, jongk.lee@samsung.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pancreatitis, Cholecystitis - Occurrence rate : % (time frame: 3 months after procedure). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jul 2017.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in